Search

Your search keyword '"Oberthuer, André"' showing total 213 results
Start Over Author "Oberthuer, André"
213 results on '"Oberthuer, André"'

6. Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma

Author

Asgharzadeh, Shahab, Salo, Jill A, Ji, Lingyun, Oberthuer, André, Fischer, Matthias, Berthold, Frank, Hadjidaniel, Michael, Liu, Cathy Wei-Yao, Metelitsa, Leonid S, Pique-Regi, Roger, Wakamatsu, Peter, Villablanca, Judith G, Kreissman, Susan G, Matthay, Katherine K, Shimada, Hiroyuki, London, Wendy B, Sposto, Richard, and Seeger, Robert C

Subjects
Rare Diseases, Pediatric, Neuroblastoma, Cancer, Genetics, Pediatric Cancer, Neurosciences, Clinical Research, 2.1 Biological and endogenous factors, Aetiology, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Antigens, CD, Antigens, Differentiation, Myelomonocytic, Calcium-Binding Proteins, Child, Preschool, DNA-Binding Proteins, Disease Progression, Disease-Free Survival, Gene Amplification, Humans, Infant, Inflammation, Macrophages, Microfilament Proteins, N-Myc Proto-Oncogene Protein, Neoplasm Metastasis, Nuclear Proteins, Oncogene Proteins, Prognosis, Receptor, trkB, Receptors, Cell Surface, Receptors, Interleukin-6, Trans-Activators, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeChildren diagnosed at age ≥ 18 months with metastatic MYCN-nonamplified neuroblastoma (NBL-NA) are at high risk for disease relapse, whereas those diagnosed at age < 18 months are nearly always cured. In this study, we investigated the hypothesis that expression of genes related to tumor-associated inflammatory cells correlates with the observed differences in survival by age at diagnosis and contributes to a prognostic signature.MethodsTumor-associated macrophages (TAMs) in localized and metastatic neuroblastomas (n = 71) were assessed by immunohistochemistry. Expression of 44 genes representing tumor and inflammatory cells was quantified in 133 metastatic NBL-NAs to assess age-dependent expression and to develop a logistic regression model to provide low- and high-risk scores for predicting progression-free survival (PFS). Tumors from high-risk patients enrolled onto two additional studies (n = 91) served as independent validation cohorts.ResultsMetastatic neuroblastomas had higher infiltration of TAMs than locoregional tumors, and metastatic tumors diagnosed in patients at age ≥ 18 months had higher expression of inflammation-related genes than those in patients diagnosed at age < 18 months. Expression of genes representing TAMs (CD33/CD16/IL6R/IL10/FCGR3) contributed to 25% of the accuracy of a novel 14-gene tumor classification score. PFS at 5 years for children diagnosed at age ≥ 18 months with NBL-NA with a low- versus high-risk score was 47% versus 12%, 57% versus 8%, and 50% versus 20% in three independent clinical trials, respectively.ConclusionThese data suggest that interactions between tumor and inflammatory cells may contribute to the clinical metastatic neuroblastoma phenotype, improve prognostication, and reveal novel therapeutic targets.

Published
2012

9. Supplementary Table 2 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

Author

Oberthuer, André, primary, Juraeva, Dilafruz, primary, Hero, Barbara, primary, Volland, Ruth, primary, Sterz, Carolina, primary, Schmidt, Rene, primary, Faldum, Andreas, primary, Kahlert, Yvonne, primary, Engesser, Anne, primary, Asgharzadeh, Shahab, primary, Seeger, Robert, primary, Ohira, Miki, primary, Nakagawara, Akira, primary, Scaruffi, Paola, primary, Tonini, Gian Paolo, primary, Janoueix-Lerosey, Isabelle, primary, Delattre, Olivier, primary, Schleiermacher, Gudrun, primary, Vandesompele, Jo, primary, Speleman, Frank, primary, Noguera, Rosa, primary, Piqueras, Marta, primary, Bénard, Jean, primary, Valent, Alexander, primary, Avigad, Smadar, primary, Yaniv, Isaac, primary, Grundy, Richard G., primary, Ortmann, Monika, primary, Shao, Chunxuan, primary, Schwab, Manfred, primary, Eils, Roland, primary, Simon, Thorsten, primary, Theissen, Jessica, primary, Berthold, Frank, primary, Westermann, Frank, primary, Brors, Benedikt, primary, and Fischer, Matthias, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 2 from Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature

Author

De Preter, Katleen, primary, Vermeulen, Joëlle, primary, Brors, Benedikt, primary, Delattre, Olivier, primary, Eggert, Angelika, primary, Fischer, Matthias, primary, Janoueix-Lerosey, Isabelle, primary, Lavarino, Cinzia, primary, Maris, John M., primary, Mora, Jaume, primary, Nakagawara, Akira, primary, Oberthuer, André, primary, Ohira, Miki, primary, Schleiermacher, Gudrun, primary, Schramm, Alexander, primary, Schulte, Johannes H., primary, Wang, Qun, primary, Westermann, Frank, primary, Speleman, Frank, primary, and Vandesompele, Jo, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Data 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

Author

Oberthuer, André, primary, Juraeva, Dilafruz, primary, Hero, Barbara, primary, Volland, Ruth, primary, Sterz, Carolina, primary, Schmidt, Rene, primary, Faldum, Andreas, primary, Kahlert, Yvonne, primary, Engesser, Anne, primary, Asgharzadeh, Shahab, primary, Seeger, Robert, primary, Ohira, Miki, primary, Nakagawara, Akira, primary, Scaruffi, Paola, primary, Tonini, Gian Paolo, primary, Janoueix-Lerosey, Isabelle, primary, Delattre, Olivier, primary, Schleiermacher, Gudrun, primary, Vandesompele, Jo, primary, Speleman, Frank, primary, Noguera, Rosa, primary, Piqueras, Marta, primary, Bénard, Jean, primary, Valent, Alexander, primary, Avigad, Smadar, primary, Yaniv, Isaac, primary, Grundy, Richard G., primary, Ortmann, Monika, primary, Shao, Chunxuan, primary, Schwab, Manfred, primary, Eils, Roland, primary, Simon, Thorsten, primary, Theissen, Jessica, primary, Berthold, Frank, primary, Westermann, Frank, primary, Brors, Benedikt, primary, and Fischer, Matthias, primary

Published
2023
Full Text
View/download PDF

13. Data from A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma

Author

Garcia, Idoia, primary, Mayol, Gemma, primary, Ríos, José, primary, Domenech, Gema, primary, Cheung, Nai-Kong V., primary, Oberthuer, André, primary, Fischer, Matthias, primary, Maris, John M., primary, Brodeur, Garrett M., primary, Hero, Barbara, primary, Rodríguez, Eva, primary, Suñol, Mariona, primary, Galvan, Patricia, primary, de Torres, Carmen, primary, Mora, Jaume, primary, and Lavarino, Cinzia, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Table 3 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

Author

Oberthuer, André, primary, Juraeva, Dilafruz, primary, Hero, Barbara, primary, Volland, Ruth, primary, Sterz, Carolina, primary, Schmidt, Rene, primary, Faldum, Andreas, primary, Kahlert, Yvonne, primary, Engesser, Anne, primary, Asgharzadeh, Shahab, primary, Seeger, Robert, primary, Ohira, Miki, primary, Nakagawara, Akira, primary, Scaruffi, Paola, primary, Tonini, Gian Paolo, primary, Janoueix-Lerosey, Isabelle, primary, Delattre, Olivier, primary, Schleiermacher, Gudrun, primary, Vandesompele, Jo, primary, Speleman, Frank, primary, Noguera, Rosa, primary, Piqueras, Marta, primary, Bénard, Jean, primary, Valent, Alexander, primary, Avigad, Smadar, primary, Yaniv, Isaac, primary, Grundy, Richard G., primary, Ortmann, Monika, primary, Shao, Chunxuan, primary, Schwab, Manfred, primary, Eils, Roland, primary, Simon, Thorsten, primary, Theissen, Jessica, primary, Berthold, Frank, primary, Westermann, Frank, primary, Brors, Benedikt, primary, and Fischer, Matthias, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

Author

Oberthuer, André, primary, Juraeva, Dilafruz, primary, Hero, Barbara, primary, Volland, Ruth, primary, Sterz, Carolina, primary, Schmidt, Rene, primary, Faldum, Andreas, primary, Kahlert, Yvonne, primary, Engesser, Anne, primary, Asgharzadeh, Shahab, primary, Seeger, Robert, primary, Ohira, Miki, primary, Nakagawara, Akira, primary, Scaruffi, Paola, primary, Tonini, Gian Paolo, primary, Janoueix-Lerosey, Isabelle, primary, Delattre, Olivier, primary, Schleiermacher, Gudrun, primary, Vandesompele, Jo, primary, Speleman, Frank, primary, Noguera, Rosa, primary, Piqueras, Marta, primary, Bénard, Jean, primary, Valent, Alexander, primary, Avigad, Smadar, primary, Yaniv, Isaac, primary, Grundy, Richard G., primary, Ortmann, Monika, primary, Shao, Chunxuan, primary, Schwab, Manfred, primary, Eils, Roland, primary, Simon, Thorsten, primary, Theissen, Jessica, primary, Berthold, Frank, primary, Westermann, Frank, primary, Brors, Benedikt, primary, and Fischer, Matthias, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 5 from A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma

Author

Garcia, Idoia, primary, Mayol, Gemma, primary, Ríos, José, primary, Domenech, Gema, primary, Cheung, Nai-Kong V., primary, Oberthuer, André, primary, Fischer, Matthias, primary, Maris, John M., primary, Brodeur, Garrett M., primary, Hero, Barbara, primary, Rodríguez, Eva, primary, Suñol, Mariona, primary, Galvan, Patricia, primary, de Torres, Carmen, primary, Mora, Jaume, primary, and Lavarino, Cinzia, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table 4 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

Author

Oberthuer, André, primary, Juraeva, Dilafruz, primary, Hero, Barbara, primary, Volland, Ruth, primary, Sterz, Carolina, primary, Schmidt, Rene, primary, Faldum, Andreas, primary, Kahlert, Yvonne, primary, Engesser, Anne, primary, Asgharzadeh, Shahab, primary, Seeger, Robert, primary, Ohira, Miki, primary, Nakagawara, Akira, primary, Scaruffi, Paola, primary, Tonini, Gian Paolo, primary, Janoueix-Lerosey, Isabelle, primary, Delattre, Olivier, primary, Schleiermacher, Gudrun, primary, Vandesompele, Jo, primary, Speleman, Frank, primary, Noguera, Rosa, primary, Piqueras, Marta, primary, Bénard, Jean, primary, Valent, Alexander, primary, Avigad, Smadar, primary, Yaniv, Isaac, primary, Grundy, Richard G., primary, Ortmann, Monika, primary, Shao, Chunxuan, primary, Schwab, Manfred, primary, Eils, Roland, primary, Simon, Thorsten, primary, Theissen, Jessica, primary, Berthold, Frank, primary, Westermann, Frank, primary, Brors, Benedikt, primary, and Fischer, Matthias, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

Author

Oberthuer, André, primary, Juraeva, Dilafruz, primary, Hero, Barbara, primary, Volland, Ruth, primary, Sterz, Carolina, primary, Schmidt, Rene, primary, Faldum, Andreas, primary, Kahlert, Yvonne, primary, Engesser, Anne, primary, Asgharzadeh, Shahab, primary, Seeger, Robert, primary, Ohira, Miki, primary, Nakagawara, Akira, primary, Scaruffi, Paola, primary, Tonini, Gian Paolo, primary, Janoueix-Lerosey, Isabelle, primary, Delattre, Olivier, primary, Schleiermacher, Gudrun, primary, Vandesompele, Jo, primary, Speleman, Frank, primary, Noguera, Rosa, primary, Piqueras, Marta, primary, Bénard, Jean, primary, Valent, Alexander, primary, Avigad, Smadar, primary, Yaniv, Isaac, primary, Grundy, Richard G., primary, Ortmann, Monika, primary, Shao, Chunxuan, primary, Schwab, Manfred, primary, Eils, Roland, primary, Simon, Thorsten, primary, Theissen, Jessica, primary, Berthold, Frank, primary, Westermann, Frank, primary, Brors, Benedikt, primary, and Fischer, Matthias, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Table 1 from A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma

Author

Garcia, Idoia, primary, Mayol, Gemma, primary, Ríos, José, primary, Domenech, Gema, primary, Cheung, Nai-Kong V., primary, Oberthuer, André, primary, Fischer, Matthias, primary, Maris, John M., primary, Brodeur, Garrett M., primary, Hero, Barbara, primary, Rodríguez, Eva, primary, Suñol, Mariona, primary, Galvan, Patricia, primary, de Torres, Carmen, primary, Mora, Jaume, primary, and Lavarino, Cinzia, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figures 1-11, Tables 2-4 from A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma

Author

Garcia, Idoia, primary, Mayol, Gemma, primary, Ríos, José, primary, Domenech, Gema, primary, Cheung, Nai-Kong V., primary, Oberthuer, André, primary, Fischer, Matthias, primary, Maris, John M., primary, Brodeur, Garrett M., primary, Hero, Barbara, primary, Rodríguez, Eva, primary, Suñol, Mariona, primary, Galvan, Patricia, primary, de Torres, Carmen, primary, Mora, Jaume, primary, and Lavarino, Cinzia, primary

Published
2023
Full Text
View/download PDF

22. Legends to Supplementaries from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

Author

Oberthuer, André, primary, Juraeva, Dilafruz, primary, Hero, Barbara, primary, Volland, Ruth, primary, Sterz, Carolina, primary, Schmidt, Rene, primary, Faldum, Andreas, primary, Kahlert, Yvonne, primary, Engesser, Anne, primary, Asgharzadeh, Shahab, primary, Seeger, Robert, primary, Ohira, Miki, primary, Nakagawara, Akira, primary, Scaruffi, Paola, primary, Tonini, Gian Paolo, primary, Janoueix-Lerosey, Isabelle, primary, Delattre, Olivier, primary, Schleiermacher, Gudrun, primary, Vandesompele, Jo, primary, Speleman, Frank, primary, Noguera, Rosa, primary, Piqueras, Marta, primary, Bénard, Jean, primary, Valent, Alexander, primary, Avigad, Smadar, primary, Yaniv, Isaac, primary, Grundy, Richard G., primary, Ortmann, Monika, primary, Shao, Chunxuan, primary, Schwab, Manfred, primary, Eils, Roland, primary, Simon, Thorsten, primary, Theissen, Jessica, primary, Berthold, Frank, primary, Westermann, Frank, primary, Brors, Benedikt, primary, and Fischer, Matthias, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Data from Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature

Author

De Preter, Katleen, primary, Vermeulen, Joëlle, primary, Brors, Benedikt, primary, Delattre, Olivier, primary, Eggert, Angelika, primary, Fischer, Matthias, primary, Janoueix-Lerosey, Isabelle, primary, Lavarino, Cinzia, primary, Maris, John M., primary, Mora, Jaume, primary, Nakagawara, Akira, primary, Oberthuer, André, primary, Ohira, Miki, primary, Schleiermacher, Gudrun, primary, Schramm, Alexander, primary, Schulte, Johannes H., primary, Wang, Qun, primary, Westermann, Frank, primary, Speleman, Frank, primary, and Vandesompele, Jo, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Data 2 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers

Author

Oberthuer, André, primary, Juraeva, Dilafruz, primary, Hero, Barbara, primary, Volland, Ruth, primary, Sterz, Carolina, primary, Schmidt, Rene, primary, Faldum, Andreas, primary, Kahlert, Yvonne, primary, Engesser, Anne, primary, Asgharzadeh, Shahab, primary, Seeger, Robert, primary, Ohira, Miki, primary, Nakagawara, Akira, primary, Scaruffi, Paola, primary, Tonini, Gian Paolo, primary, Janoueix-Lerosey, Isabelle, primary, Delattre, Olivier, primary, Schleiermacher, Gudrun, primary, Vandesompele, Jo, primary, Speleman, Frank, primary, Noguera, Rosa, primary, Piqueras, Marta, primary, Bénard, Jean, primary, Valent, Alexander, primary, Avigad, Smadar, primary, Yaniv, Isaac, primary, Grundy, Richard G., primary, Ortmann, Monika, primary, Shao, Chunxuan, primary, Schwab, Manfred, primary, Eils, Roland, primary, Simon, Thorsten, primary, Theissen, Jessica, primary, Berthold, Frank, primary, Westermann, Frank, primary, Brors, Benedikt, primary, and Fischer, Matthias, primary

Published
2023
Full Text
View/download PDF

27. Data from N-Myc Regulates Expression of the Detoxifying Enzyme Glutathione Transferase GSTP1, a Marker of Poor Outcome in Neuroblastoma

Author

Fletcher, Jamie I., primary, Gherardi, Samuele, primary, Murray, Jayne, primary, Burkhart, Catherine A., primary, Russell, Amanda, primary, Valli, Emanuele, primary, Smith, Janice, primary, Oberthuer, André, primary, Ashton, Lesley J., primary, London, Wendy B., primary, Marshall, Glenn M., primary, Norris, Murray D., primary, Perini, Giovanni, primary, and Haber, Michelle, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Tables 1-6, Figures 1-4 from N-Myc Regulates Expression of the Detoxifying Enzyme Glutathione Transferase GSTP1, a Marker of Poor Outcome in Neuroblastoma

Author

Fletcher, Jamie I., primary, Gherardi, Samuele, primary, Murray, Jayne, primary, Burkhart, Catherine A., primary, Russell, Amanda, primary, Valli, Emanuele, primary, Smith, Janice, primary, Oberthuer, André, primary, Ashton, Lesley J., primary, London, Wendy B., primary, Marshall, Glenn M., primary, Norris, Murray D., primary, Perini, Giovanni, primary, and Haber, Michelle, primary

Published
2023
Full Text
View/download PDF

35. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study

Author

Vermeulen, Joëlle, De Preter, Katleen, Naranjo, Arlene, Vercruysse, Liesbeth, Van Roy, Nadine, Hellemans, Jan, Swerts, Katrien, Bravo, Sophie, Scaruffi, Paola, Tonini, Gian Paolo, De Bernardi, Bruno, Noguera, Rosa, Piqueras, Marta, Cañete, Adela, Castel, Victoria, Janoueix-Lerosey, Isabelle, Delattre, Olivier, Schleiermacher, Gudrun, Michon, Jean, Combaret, Valérie, Fischer, Matthias, Oberthuer, André, Ambros, Peter F, Beiske, Klaus, Bénard, Jean, Marques, Bárbara, Rubie, Hervé, Kohler, Janice, Pötschger, Ulrike, Ladenstein, Ruth, Hogarty, Michael D, McGrady, Patrick, London, Wendy B, Laureys, Geneviève, Speleman, Frank, and Vandesompele, Jo

Published
2009
Full Text
View/download PDF

40. Maximum predictive power of the microarray-based models for clinical outcomes is limited by correlation between endpoint and gene expression profile

Author

Zhao Chen, Shi Leming, Tong Weida, Shaughnessy John D, Oberthuer André, Pusztai Lajos, Deng Youping, Symmans W Fraser, and Shi Tieliu

Subjects
Biotechnology, TP248.13-248.65, Genetics, QH426-470
Abstract

Abstract Background Microarray data have been used for gene signature selection to predict clinical outcomes. Many studies have attempted to identify factors that affect models' performance with only little success. Fine-tuning of model parameters and optimizing each step of the modeling process often results in over-fitting problems without improving performance. Results We propose a quantitative measurement, termed consistency degree, to detect the correlation between disease endpoint and gene expression profile. Different endpoints were shown to have different consistency degrees to gene expression profiles. The validity of this measurement to estimate the consistency was tested with significance at a p-value less than 2.2e-16 for all of the studied endpoints. According to the consistency degree score, overall survival milestone outcome of multiple myeloma was proposed to extend from 730 days to 1561 days, which is more consistent with gene expression profile. Conclusion For various clinical endpoints, the maximum predictive powers of different microarray-based models are limited by the correlation between endpoint and gene expression profile of disease samples as indicated by the consistency degree score. In addition, previous defined clinical outcomes can also be reassessed and refined more coherent according to related disease gene expression profile. Our findings point to an entirely new direction for assessing the microarray-based predictive models and provide important information to gene signature based clinical applications.

Published
2011
Full Text
View/download PDF

48. Cross-study analysis of gene expression data for intermediate neuroblastoma identifies two biological subtypes

Author

Eils Roland, Westermann Frank, Fischer Matthias, Oberthuer André, Warnat Patrick, and Brors Benedikt

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Abstract Background Neuroblastoma patients show heterogeneous clinical courses ranging from life-threatening progression to spontaneous regression. Recently, gene expression profiles of neuroblastoma tumours were associated with clinically different phenotypes. However, such data is still rare for important patient subgroups, such as patients with MYCN non-amplified advanced stage disease. Prediction of the individual course of disease and optimal therapy selection in this cohort is challenging. Additional research effort is needed to describe the patterns of gene expression in this cohort and to identify reliable prognostic markers for this subset of patients. Methods We combined gene expression data from two studies in a meta-analysis in order to investigate differences in gene expression of advanced stage (3 or 4) tumours without MYCN amplification that show contrasting outcomes (alive or dead) at five years after initial diagnosis. In addition, a predictive model for outcome was generated. Gene expression profiles from 66 patients were included from two studies using different microarray platforms. Results In the combined data set, 72 genes were identified as differentially expressed by meta-analysis at a false discovery rate (FDR) of 8.33%. Meta-analysis detected 34 differentially expressed genes that were not found as significant in either single study. Outcome prediction based on data of both studies resulted in a predictive accuracy of 77%. Moreover, the genes that were differentially expressed in subgroups of advanced stage patients without MYCN amplification accurately separated MYCN amplified tumours from low stage tumours without MYCN amplification. Conclusion Our findings support the hypothesis that neuroblastoma consists of two biologically distinct subgroups that differ by characteristic gene expression patterns, which are associated with divergent clinical outcome.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results